Handelsbanken Fonder Ab Iveric Bio, Inc. Transaction History

Handelsbanken Fonder Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	SELL	$26.24 - $39.63 $115,456 - $174,372	-4,400 Reduced 14.62%	25,700 $1.01 Million
Q1 2023 Apr 28, 2023	BUY	$18.67 - $24.56 $93,350 - $122,800	5,000 Added 19.92%	30,100 $732,000
Q4 2022 Feb 07, 2023	BUY	$17.24 - $23.95 $136,196 - $189,205	7,900 Added 45.93%	25,100 $537,000
Q1 2022 May 11, 2022	BUY	$12.15 - $16.83 $14,580 - $20,195	1,200 Added 7.5%	17,200 $289,000
Q4 2021 Feb 08, 2022	BUY	$13.83 - $18.78 $221,280 - $300,480	16,000 New	16,000 $268,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.